EP3349768A4 - Antibodies for generating anti-inflammatory macrophage and related uses - Google Patents

Antibodies for generating anti-inflammatory macrophage and related uses Download PDF

Info

Publication number
EP3349768A4
EP3349768A4 EP16847105.0A EP16847105A EP3349768A4 EP 3349768 A4 EP3349768 A4 EP 3349768A4 EP 16847105 A EP16847105 A EP 16847105A EP 3349768 A4 EP3349768 A4 EP 3349768A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
generating anti
related uses
inflammatory macrophage
macrophage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16847105.0A
Other languages
German (de)
French (fr)
Other versions
EP3349768A1 (en
Inventor
Kyung Ho Han
Richard A. Lerner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of EP3349768A1 publication Critical patent/EP3349768A1/en
Publication of EP3349768A4 publication Critical patent/EP3349768A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP16847105.0A 2015-09-15 2016-09-12 Antibodies for generating anti-inflammatory macrophage and related uses Withdrawn EP3349768A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562218785P 2015-09-15 2015-09-15
PCT/US2016/051290 WO2017048629A1 (en) 2015-09-15 2016-09-12 Antibodies for generating anti-inflammatory macrophage and related uses

Publications (2)

Publication Number Publication Date
EP3349768A1 EP3349768A1 (en) 2018-07-25
EP3349768A4 true EP3349768A4 (en) 2019-01-23

Family

ID=58289788

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16847105.0A Withdrawn EP3349768A4 (en) 2015-09-15 2016-09-12 Antibodies for generating anti-inflammatory macrophage and related uses

Country Status (3)

Country Link
EP (1) EP3349768A4 (en)
AU (1) AU2016324021A1 (en)
WO (1) WO2017048629A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023146860A1 (en) * 2022-01-28 2023-08-03 The George Washington University Compositions for and methods of treating a subject having inflammation
CN116445407B (en) * 2023-06-16 2023-09-08 广州正源生物技术有限公司 Extraction and amplification culture method of placenta macrophages

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060272041A1 (en) * 2001-09-24 2006-11-30 Wisotzkey Robert G Cathepsin G (CTSG) Disruptions, Compositions and Methods Relating Thereto
JP4716350B2 (en) * 2001-12-04 2011-07-06 ダナ−ファーバー キャンサー インスティテュート インク． Antibodies against latency membrane proteins and their use
JP5985987B2 (en) * 2009-10-16 2016-09-06 レ ラボラトワール セルヴィエ Monoclonal antibody against progastrin and use thereof
WO2012024309A2 (en) * 2010-08-18 2012-02-23 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
EP2708560A4 (en) * 2011-05-09 2015-01-14 Perseus Proteomics Inc Antibody specifically recognising transferrin receptor

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
B. KORKMAZ ET AL: "Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases", PHARMACOLOGICAL REVIEWS, vol. 62, no. 4, 15 November 2010 (2010-11-15), US, pages 726 - 759, XP055535637, ISSN: 0031-6997, DOI: 10.1124/pr.110.002733 *
DAVID G LOMAS ET AL: "The Control of Neutrophil Chemotaxis by Inhibitors of", J. BIOL. CHEM., 1 January 1995 (1995-01-01), pages 23437 - 23443, XP055535631, Retrieved from the Internet <URL:http://www.jbc.org/content/270/40/23437.full.pdf> [retrieved on 20181217] *
KEITH M SKUBITZ ET AL: "Preparation and Characterization of Monoclonal Antibodies to Human Neutrophil Cathepsin G, Lactoferrin, Eosinophil Peroxidase, and Eosinophil Major Basic Protein", JOURNAL OF LEUKOCYTE BIOLOGY, 1 January 1989 (1989-01-01), pages 109 - 118, XP055535628, Retrieved from the Internet <URL:https://jlb.onlinelibrary.wiley.com/doi/pdf/10.1002/jlb.46.2.109> [retrieved on 20181217] *
NADINE JETTEN ET AL: "Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo", ANGIOGENESIS, vol. 17, no. 1, 8 September 2013 (2013-09-08), NL, pages 109 - 118, XP055535574, ISSN: 0969-6970, DOI: 10.1007/s10456-013-9381-6 *
NAUDER FARADAY ET AL: "Cathepsin G-Dependent Modulation of Platelet Thrombus Formation In Vivo by Blood Neutrophils", PLOS ONE, vol. 8, no. 8, 5 August 2013 (2013-08-05), pages e71447, XP055535633, DOI: 10.1371/journal.pone.0071447 *
PAOLO CONROTTO ET AL: "Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comnparative mass spectrometry analysis", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 123, no. 12, 15 December 2008 (2008-12-15), pages 2856 - 2864, XP002663352, ISSN: 0020-7136, [retrieved on 20080916], DOI: 10.1002/IJC.23861 *
RICHARD A. LERNER ET AL: "Antibodies from combinatorial libraries use functional receptor pleiotropism to regulate cell fates", QUARTERLY REVIEWS OF BIOPHYSICS., vol. 48, no. 04, 16 July 2015 (2015-07-16), pages 389 - 394, XP055238228, ISSN: 0033-5835, DOI: 10.1017/S0033583515000049 *
See also references of WO2017048629A1 *

Also Published As

Publication number Publication date
EP3349768A1 (en) 2018-07-25
AU2016324021A1 (en) 2018-04-12
WO2017048629A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
EP3247435A4 (en) Ultrasonic vaporizing element
EP3334757A4 (en) Anti-tigit antibodies
EP3305103A4 (en) Atomization unit
EP3297671A4 (en) Anti-ror1 antibodies
EP3336220A4 (en) Gas generator
EP3354729A4 (en) Anti-garp antibody
EP3318754A4 (en) Magnus-type thrust generating device
EP3229838A4 (en) Anti-c10orf54 antibodies and uses thereof
EP3315035A4 (en) Atomization unit
EP3267139A4 (en) Turbulence generating device
EP3283516A4 (en) Anti-pacap antibodies and uses thereof
EP3252074A4 (en) Anti-alk2 antibody
EP3192518A4 (en) Anti-inflammatory agent
EP3349794A4 (en) Anti-cd115 antibodies
EP3433720A4 (en) Arbitrary view generation
EP3381941A4 (en) Anti-epha4 antibody
EP3307030A4 (en) Plasma generating device
EP3366526A4 (en) Gas generator
EP3369630A4 (en) Gas generator
EP3423364A4 (en) Carton with expansion features
EP3166609A4 (en) Anti-cancer compounds target ral gtpases and methods of using the same
EP3336185A4 (en) Antibody
EP3194035A4 (en) Wave generating systems
AU2016349786B2 (en) Anti-CD3-folate conjugates and their uses
EP3336184A4 (en) Antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190104

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/12 20150101ALI20181220BHEP

Ipc: C12N 5/0786 20100101ALI20181220BHEP

Ipc: C07K 16/40 20060101AFI20181220BHEP

Ipc: A61K 49/16 20060101ALI20181220BHEP

Ipc: A61K 35/15 20150101ALI20181220BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190802